Jacobs Levy Equity Management Inc. Buys 304,420 Shares of Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Jacobs Levy Equity Management Inc. significantly increased its holdings in Aurinia Pharmaceuticals by 2,299.9%, owning 317,656 shares worth approximately $2.55 million after purchasing an additional 304,420 shares.
• Recent insider trading shows Director Kevin Tang purchased 1 million shares at $10.12 per share, bringing his total ownership to 11,029,500 shares, valued at around $111.6 million.
• Wall Street analysts have a consensus rating of "Buy" for Aurinia Pharmaceuticals, with price targets ranging from $9.00 to $17.00, indicating positive expectations for the company's growth.

Jacobs Levy Equity Management Inc. raised its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 2,299.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 317,656 shares of the biotechnology company's stock after acquiring an additional 304,420 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.23% of Aurinia Pharmaceuticals worth $2,554,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in Aurinia Pharmaceuticals in the fourth quarter valued at about $27,000. Tower Research Capital LLC TRC lifted its holdings in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC bought a new position in Aurinia Pharmaceuticals in the fourth quarter valued at about $31,000. GAMMA Investing LLC lifted its holdings in Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after acquiring an additional 1,744 shares during the period. Finally, MAI Capital Management bought a new position in Aurinia Pharmaceuticals in the first quarter valued at about $39,000. Institutional investors own 36.83% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AUPH. Royal Bank Of Canada increased their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Aurinia Pharmaceuticals has an average rating of "Buy" and a consensus target price of $12.00.

Aurinia Pharmaceuticals Trading Down 0.3%

AUPH traded down $0.04 during trading hours on Monday, reaching $12.70. 180,612 shares of the company's stock traded hands, compared to its average volume of 1,621,590. The firm has a 50-day moving average price of $10.76 and a 200 day moving average price of $8.99. Aurinia Pharmaceuticals Inc has a 52-week low of $6.55 and a 52-week high of $12.87. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $1.67 billion, a PE ratio of 29.48 and a beta of 1.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $70.01 million during the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Kevin Tang bought 200,000 shares of the stock in a transaction on Tuesday, August 5th. The stock was acquired at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the acquisition, the director owned 11,329,500 shares of the company's stock, valued at $132,328,560. This represents a 1.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders acquired 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.